Welcome to our dedicated page for DBV Technologies S.A. SEC filings (Ticker: DBVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DBV Technologies S.A. filings document the disclosure record of a French late-stage biopharmaceutical issuer with American Depositary Shares listed under DBVT. The filings identify ordinary shares and ADSs, with each ADS representing five ordinary shares, and cover the company’s VIASKIN patch technology, epicutaneous immunotherapy approach, and food-allergy development programs.
Recent SEC materials include Form 8-K reports for operating results, business highlights, clinical-data releases for the Phase 3 VITESSE study, warrant-related financing events, and governance matters. Proxy materials describe shareholder meeting proposals, board and committee matters, executive compensation, and equity-award plans.
DBV Technologies S.A. reported that investment entity MPM BioImpact LLC has filed an amended Schedule 13G reflecting its beneficial ownership of the company’s equity. MPM BioImpact LLC is the beneficial owner of 18,331,420 Ordinary Shares of DBV Technologies S.A.
These holdings represent 6.2% of the outstanding Ordinary Shares. The position is held with sole voting power and sole dispositive power over all 18,331,420 Ordinary Shares. The reported stake is represented by American Depositary Shares, with each ADS corresponding to five Ordinary Shares.
DBV Technologies S.A. is reported to have a new significant shareholder group led by RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. These reporting persons collectively report beneficial ownership of 18,288,220 ordinary shares of DBV Technologies, held through 3,657,644 American Depositary Shares (ADSs), with each ADS representing five ordinary shares.
The position represents 5.8% of DBV Technologies’ ordinary shares. This percentage is calculated based on 295,915,176 ordinary shares outstanding (net of 146,321 treasury shares) as of July 16, 2026, plus 18,288,220 ordinary shares issued to the Fund in the form of ADSs pursuant to an at-the-market offering on July 30, 2026. The reporting persons describe how voting and investment power over these securities is delegated within the RA Capital structure and include customary beneficial ownership disclaimers.
DBV Technologies S.A. Chief Medical Officer Mohideen Pharis reported a sale of 464 ordinary shares on July 29, 2026 at $2.70 per share. The shares were sold to satisfy withholding tax obligations upon the vesting of restricted stock units. After this transaction, Pharis directly held 144,531 ordinary shares, which may be represented by American Depositary Shares, each currently representing five ordinary shares.
DBV Technologies S.A. is establishing an automatic shelf registration statement on Form S-3, allowing the company and any selling securityholders to offer, from time to time, an indeterminate amount of ordinary shares, ADSs representing ordinary shares, and warrants. The registration is filed as a well-known seasoned issuer shelf, with no limit on the aggregate amount of securities that may be offered under this program.
Offerings may be primary sales by DBV or resales by selling securityholders and can be conducted in various ways, including direct sales, offerings through agents, or through underwriters and dealers on a continuous or delayed basis. DBV’s ADSs trade on Nasdaq under “DBVT,” with a last reported price of $13.86 per ADS on July 23, 2026, and its ordinary shares trade on Euronext Paris under “DBV” at €2.374 per share on the same date; warrants are not listed on any market. Unless specified otherwise in a supplement, DBV will use net proceeds from its own offerings for working capital and general corporate purposes and will not receive proceeds from sales by selling securityholders.
The prospectus also summarizes DBV’s business as a late stage specialty biopharmaceutical company developing its Viaskin epicutaneous immunotherapy platform, including Viaskin Peanut patches for children with peanut allergy. As of July 23, 2026, DBV had 296,085,697 ordinary shares issued and outstanding, fully paid, with no preferred shares. Extensive disclosure is provided on French corporate law, shareholder rights, ADS terms, and ownership and notification thresholds that apply to DBV’s equity securities.
DBV Technologies reported second-quarter and half-year 2026 results, highlighting continued investment in its VIASKIN® Peanut Patch program and commercial readiness. Under U.S. GAAP, operating income was $1.6 million for the first half of 2026, while operating expenses rose to $100.1 million, driven by higher R&D, sales and marketing, and general and administrative costs.
The company recorded a half-year net loss of $98.0 million and basic/diluted net loss per share of $(0.23), compared with $(0.58) a year earlier, reflecting a significantly strengthened equity base. Net cash used in operating and investing activities increased to $102.6 million. Cash and cash equivalents were $174.9 million as of June 30, 2026, and management currently forecasts funding into the third quarter of 2027, assuming continued focus on the VIASKIN® Peanut Patch and related regulatory and commercial activities, including a planned BLA submission in the third quarter of 2026.
DBV Technologies S.A. is a late-stage biopharmaceutical company developing the Viaskin epicutaneous patch platform, led by Viaskin Peanut for children with peanut allergy. For the quarter ended June 30, 2026, there was no product revenue; operating income of $0.7 million came solely from the French research tax credit.
Quarterly operating expenses were $51.3 million, including research and development of $31.2 million, sales and marketing of $5.5 million, and general and administrative of $14.6 million, reflecting scaling for Biologics License Application (BLA) execution and commercial launch preparedness. Net loss was $50.4 million for the quarter and $98.0 million for the first six months, with basic and diluted loss per share of $(0.12) and $(0.23), respectively.
Cash and cash equivalents totaled $174.9 million at June 30, 2026. Net cash used in operating activities was $101.7 million and in investing activities $0.9 million in the first half, partially offset by $89.0 million of financing inflows from warrant exercises linked to the March 2025 PIPE financing. Management estimates existing resources will fund operations into the third quarter of 2027. The company is preparing a BLA for Viaskin Peanut in children aged 4–7 years in the third quarter of 2026 and a potential toddler BLA in the second half of 2026, supported by expanded manufacturing agreements and commercialization letters of intent.
DBV Technologies S.A. provided an update on its planned Biologics License Application (BLA) seeking U.S. marketing approval for the VIASKIN® Peanut Patch in children aged four through seven years. After detailed, collaborative discussions with the FDA on data organization and formatting, the agency has not requested additional data. DBV will use the feedback to refine the submission and now anticipates filing the BLA in the third quarter of 2026. The company will discuss the update on a conference call and webcast on June 29 at 5:00 p.m. ET.
DBV Technologies S.A. approved a new 2026 Performance Share Unit Plan and granted its CEO, Daniel Tassé, 4,060,000 Performance Share Units (PSUs). Each PSU is a conditional right to receive one ordinary share.
Vesting depends on FDA approval of biologics license applications for Viaskin Peanut in specified age groups and a continued employment condition through July 1, 2028. PSUs that do not meet performance conditions by this date are forfeited. Vested shares are scheduled for delivery in four installments on July 1, 2028, January 1, 2029, July 1, 2029 and January 1, 2030.
Upon a Change in Control, performance conditions are deemed achieved and only the employment condition remains. The plan includes special rules for death, disability, qualifying retirement, termination without cause or for good reason, Section 409A deferral for specified employees, and allows the Board to substitute equivalent cash if the CEO is not a French tax resident at delivery.
DBV Technologies S.A. reported the results of its Annual Combined Meeting of Shareholders and related changes to its bylaws. Shareholders approved amendments to Articles 18 and 21 to align the Ordinary Share Record Date with French decree nº2026-94 of February 13, 2026. They also amended Article 15 to set a Chief Executive Officer age limit of 70 years, with the CEO’s mandate ending at the shareholders’ meeting approving the financial statements for the year in which that age is reached. Across the ordinary and extraordinary agendas, the thirty-nine proposals received strong support, with many resolutions attracting around 190 million votes in favor versus much smaller opposition, confirming broad shareholder backing for the updated governance framework.
DBV Technologies S.A. ownership update: MPM BioImpact LLC reports beneficial ownership of 26,066,806 Ordinary Shares, equal to 8.8% of the outstanding Ordinary Shares. The filing states the outstanding Ordinary Shares were 296,042,447 as of March 31, 2026. The report is signed by Christopher Wolf, Chief Financial Officer.